Anti-platelet aggregation

Rhynchophylline
Catalog No: CFN98131

Rhynchophylline, a noncompetitive antagonist of the NMDA receptor, which has anti-inflammatory, anti-hypertension, cardiacprotective and neuroprotective activities. Rhynchophylline can markedly inhibit rabbit platelet aggregation induced by ADP or thrombin possibly by depressing the inflow of Ca2+ and the rise of the cytoplasmic free calcium level in platelet.Rhynchophylline can reduce the systolic blood pressure (SBP) of spontaneously hypertensive rats (SHR) significantly, decrease plasma Ang II, ADMA, and AT1R levels, and promote serum NO and NOS levels, which has the protection of vascular endothelial function.

Sideroxylin
Catalog No: CFN98394

Sideroxylin can synergistically enhance the antimicrobial activity of the alkaloid berberine (also a constituent of H. canadensis) against Staphylococcus aureus by inhibition of the NorA multidrug resistance pump.

Murrayone
Catalog No: CFN98505

Murrayone can significantly inhibit the abnormal increase of platelet aggregation induced by ADP.

Protopine hydrochloride
Catalog No: CFN98520

Protopine has antiplatelet effects,which is due to inhibition on thromboxane formation and phosphoinositides breakdown and then lead to the decrease of intracellular calcium concentration.Protopine seems to inhibit the heterotypic cell adhesion between MDA-MB-231 cells, and human umbilical vein endothelial cells by changing the expression of adhesive factors.

Anwulignan
Catalog No: CFN98539

Anwuligan has antimicrobial and anticariogenic activity against Streptococcus mutans and other streptococcus species. It also shows antioxidant, free radical scavenging, and neuroprotective activities. (+)-Anwulignan has inhibitory effects on platelets aggregation induced by adenosine diphosphate (ADP) and platelet activating factor(PAF) in vitro.